Contribute Try STAT+ Today

Launching a clinical trial for a drug intended to treat severe asthma during a respiratory pandemic — particularly one that seems to hit people with some types of asthma particularly hard — could be a risky move.

But that’s precisely what Kinaset Therapeutics is planning to do early next year. After testing its drug in healthy people, the company hopes to start recruiting people with severe non-eosinophilic asthma — a subtype of asthma with inflammation that isn’t associated with high levels of one type of white blood cells. The company hopes its inhalable drug might help people with this type of asthma better control their condition.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.